37 results about "CYP2C9" patented technology

The invention provides compositions and methods for treating neurodegenerative disorders. A method of the invention involves administering to an individual in need of treatment a composition having an R-NSAID and an NMDA antagonist. Another method of the invention involves administering to an individual in need of treatment a composition having at least two compounds that are capable of interacting with CYP2C9, wherein at least one of said compounds is an Aβ₄₂ lowering agent. The methods and compositions of the invention are useful for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, mild cognitive impairment.

The invention discloses a detection method for the CYP2C9 gene ninth exon single nucleotide polymorphism, belonging to the technical field of the genetic engineering. The method comprises the following steps: step one, by taking the CYP2C9 gene ninth exon in a GenBank database and the exon and intron joint part sequence as a template, a pair of allele-specific nucleic acid primers are designed; the primer pair is used for amplifying the DNA sequence of the CYP2C9 gene ninth exon; and then corresponding separated nucleic acids are obtained by conducting separation and purification on the amplified product; and step two, detection is carried out on the 1739-1740 nucleotides of the CYP2C9 gene ninth exon of the separated nucleic acids so as to fix whether single nucleotide polymorphism exists or not. The invention can be used for studying the relationship between the CYP2C9 gene polymorphism in the population of China and the clinical drug safety, and provides guiding basis for the research and development of new drugs.

The invention discloses a specific primer and liquid phase chip for SNP (Single Nucleotide Polymorphism) detection of CYP2C9 (Cytochrome P4502C9), wherein the liquid phase chip comprises an ASPE primer consisting of a tag sequence of 5' end and a specific primer of 3' end aiming at target gene mutation, a microsphere coated by the anti-tag sequence, and an amplification primer; the specific primer includes: SEQ ID NO.17 and SEQ ID NO.18 aiming at G98A SNP locus, SEQ ID NO.19 and SEQ ID NO.20 aiming at G173A SNP locus, SEQ ID NO.21 and SEQ ID NO.22 aiming at C90T SNP locus, SEQ ID NO.23 and SEQ ID NO.24 aiming at A162C SNP locus, SEQ ID NO.25 and SEQ ID NO.26 aiming at C72T SNP locus, SEQ ID NO.27 and SEQ ID NO.28 aiming at T102C SNP locus, SEQ ID NO.29 and SEQ ID NO.30 aiming at A77G SNP locus, and/or SEQ ID NO.31 and SEQ ID NO.32 aiming at A167C SNP locus. The matching rate between a detection result obtained by adopting the liquid phase chip for SNP detection of CYP2C9 and a sequencing method can be 100%.

The invention discloses a multi-gene detection kit for anti-epileptic drug medication guidance and a use method thereof. A multi-PCR and fragment length/mass analysis method is used for synchronously,quickly and quantitatively detecting eight single nucleotide polymorphism (SNP) loci on four genes, including CYP2C9, CYP2C19, POLG and UGT1A4, related to anti-epileptic drug metabolism, transfer andtarget site actions. Detection includes the steps that 1, oral cast-off cells are collected and stored in a cell acquisition card or a blood sample is collected and nucleic acid is extracted; 2, thecell acquisition card or the nucleic acid in step 1 serves as a template for multi-PCR amplification; 3, according to the length/mass of PCR product fragments, the eight SNP loci, three personal genome DNA reference (huDNA) genes and a PCR product of a PCR reaction internal reference are synchronously separated; 4, results are subjected to analysis and interpretation. The kit has the advantages ofbeing quick to use, high in sensitivity, good in repeatability, high in specificity, high in flux and low in cost.

The invention discloses a detecting probe for CYP2C9*2 gene polymorphism. The nucleotide sequences of the detecting probe are selected from a sequence 1 and a sequence 2; a fluorescent group and a quenching group are respectively arranged at the ends (5'and 3'); the peak values of the wavelengths of the florescent light emitted from the fluorescent group are at different positions. Preferably, the quenching group is selected from MGB and BHQ2; preferably, the fluorescent group is selected from FAM, VIC, JOE, HEX, CY3, NED, TAMRA, ROX, TEXAS RED, CY5 and the like. The invention further discloses a primer pair used for gene amplification; the primer pair comprises a forward primer and a reverse primer; the forward primer is an oligonucleotide which consists of base sequences of a sequence 3; the reverse primer is an oligonucleotide which consists of base sequences of a sequence 4. The invention further discloses a kit which contains the primers and the probe, and a detecting method for the CYP2C9*2 gene polymorphism.

The invention discloses a cytochrome P450 gene genetic variation detecting chip. It includes the probe fixed on the solid phase carrier to hybridize with the cytochrome P450 gene nucleotide sequence and/or complementation sequence. The invention also discloses the used chip detecting method. The detecting chip can effectively detect subtype genetic variation of CYP2C9, CYP2C19, CYP2D6, CYP3A5, forecast the therapeutic effectiveness of over 40% clinic common medicine to realize individualization medical treatment.

The invention provides a reagent kit for using a molecular beacon probe for detecting human CYP2C9 gene polymorphism. The reagent kit comprises the following nucleotide sequences, a primer pair and the probe for detection, wherein the primer pair is used for amplifying polymorphic sites of rs1799853 and rs1057910 of a CYP2C9 gene. The invention further discloses application on CYP2C9 gene polymorphic site detectionand amplification of the primer and the probe. The reagent kit for using the molecular beacon probe for detecting the human CYP2C9 gene polymorphism is easy to operate, precise in result and easy to interpret, polymorphism of the sites of rs1799853 and rs1057910 of the CYP2C9 gene can be detected rapidly in PCR. Compared with a sequencing method, a method for using the molecularbeacon probe for detecting the human CYP2C9 gene polymorphism does not need to conduct a series of follow-up treatment on PCR products, the PCR amplification and detection are carried out synchronously, and a cover does not need to be opened in the whole detection process, so that risks for contaminating the PCR products are reduced, the detection time is dramatically shortened, and the detectioncost is reduced.

The invention relates to a primer composition and a kit for detecting sulfonylurea-related genes, wherein the primer composition comprises a CYP2C9 (cytochrosome P4502C9) primer set, a KCNJ11 primer set and a ABCC8 primer set, and the kit comprises the above-mentioned primer compositions. Compared with the prior art, with ARMS (the amplification refractory mutation system) technology combined withSYBR dye, the kit for rapidly, sensitively and simply detecting the polymorphisms of sulfonylurea-related genes such as CYP2C9, KCNJ11 and ABCC8 is developed, and the kit comprises a specific ARMS detection primer, an internal control primer and aPCR reaction solution. By designing ARMS primers and replacing Scorpions probes with SYBR dyes, the primer composition and the kit for detecting the sulfonylurea-related genes have the advantages of greatly reducing detection costs, being suitable for for detection of CYP2C9, KCNJ11 and ABCC8 gene polymorphisms in Chinese patients, being rapid in detection, high in sensitivity, strong in specificity, simple in method and accurate in results, and being suitable for popularization and application.

The invention discloses a Juno<TM>-based safety medication detection kit for children and a chip. The kit and the chip comprise primers at the following loci: HLA-DRB1*15:01-DQB1*06:02 loci of an HLAgene, an HLA-B*57:01 locus of the HLA gene, an HLA-B*15:02 locus of the HLA gene, an HLA-B*58:01 locus of the HLA gene, a rs267606617 locus of an MT-RNR1 gene,a rs267606618 locus of the MT-RNR1 gene,a rs267606619 locus of the MT-RNR1 gene, a rs1057910 locus of a CYP2C9 gene, a rs4244285 locus of a CYP2C19 gene, a rs4986893 locus of the CYP2C19 gene, a rs1065852 locus of a CYP2D6 gene, and a rs2242480 locus of a CYP3A4 gene.

The invention provides a primer group for gene group detection for medication guidance of anxiety patients, related application and a corresponding kit, the primer group comprises primers for detecting variation related to each gene in the gene group, and the gene group comprises the following genes: CYP2C9, CYP2C19, CYP3A4, CYP3A5, NAT2, ABCB1, SCN1A, UGT1A4 and POLG.

The invention discloses a primer capable of detecting CYP2C9*2 gene mutation, and a detection method. The invention provides a primer pair for CYP2C9*2 gene mutation, and the nucleotide sequences are shown in SEQ ID NO.1 and SEQ ID NO.2. The invention further discloses a method for detecting whether the CYP2C9*2 gene is mutated by applying the primer pair, and the method comprises the following steps: (1) extracting a to-be-detected blood sample DNA; (2) performing PCR amplification; (3) determining the PCR amplified segment sequence by adopting a Sanger method; and (4) comparing a CYP2C9*2 gene standard sequence and a sample sequence, judging detection locus base defined in the standard sequence and the corresponding locus base in the sequencing sequence, and analyzing the type of the gene mutation locus. The amplified segment is sequenced by adopting a Sanger method, and by comparing the sequencing result and the standard sequence, the mutation of the detected base can be intuitively read out, and the accuracy is high.

The invention relates to the field of genetic engineering and molecular biology, and provides a genetic typing detection primer group related to cardiovascular and cerebrovascular disease drugs, whichis used for specific amplification of nucleic acid fragments containing a site to be measured, the site to be measured comprises an rs1799853 site of a CYP2C9 gene, an rs1057910 site of the CYP2C9 gene, an rs2108622 site of a CYP4F2 gene and the like, the primer group comprises an rs1799853 primer group, an rs1057910 primer group, and an rs2108622 primer group and the like. The invention also provides a gene detection kit and a detection method. The gene detection primer group can carry out specific amplification on the nucleic acid fragments containing the sites, so that the sensitivity of gene mutation detection is high and the false positive rate is low. According to the invention, a second generation high-throughput gene sequencing technology is used to detect the genotypes of the sites to be measured, which makes the detection cycle short and the flux high.

The invention discloses a kit for detecting the curative effect of an individual hypoglycemic drug. The kit comprises a specific primer pair, a specific fluorescent probe pair, a fluorescence quantitative PCR conventional assembly and the like, and the specific primer pair is used for detecting a medication target site, namely a CYP2C9 gene and CYP2C19 gene polymorphism site of the hypoglycemic drug. The kit can be used for estimating the curative effect of the individual hypoglycemic drug by detecting the medication target site, namely the CYP2C9 gene and CYP2C19 gene polymorphism site of the hypoglycemic drug.

The invention discloses a CYP2C9 gene segment containing the 373C>T mutation, a coded protein segment and an application of the CYP2C9 gene segment, belongs to the field of biology, and relates to single base mutations. More specifically, the invention relates to a mutation site, corresponding to a 373th site of SEQ ID NO.2, of a CYP2C9 gene, a nucleic acid fragment containing the mutation site, aprotein fragment coded by the nucleic acid fragment, and an application of the nucleic acid fragment, wherein the site is mutated from wild type C to T. The mutant CYP2C9 protein, namely R125C, caused by the single base mutation has lower metabolic activity of drugs compared than wild type CYP2C9 protein, and therefore the guiding significance is provided for the medication of individuals carrying the mutation site.

The invention discloses a kit and a method for determining the genotype of a predetermined SNP (single nucleotide polymorphisms) locus of a DNA (deoxyribonucleic acid) sample to be detected. The kit comprises a first nucleic acid molecule, a second nucleic acid molecule, a first probe and a second probe, wherein the 5' terminals of the probes are labelled with fluorescence reporter groups and the 3' terminals are labelled with fluorescence quenching groups; the fluorescence reporter groups of the first and second probes are different. The kit can be used for detection and genotyping of an rs1057910 locus of a CYP2C9 gene.

Described are methods for determining a recommended dosage and/or variety of cannabis for a subject based on genetic testing. The presence or absence of genetic variants in a sample from the subject is determined and used to determine a recommended dosage of cannabis, estimate the sensitivity of the subject to cannabis, or select a subject for the treatment of a medical condition. In some embodiments the genetic variants include polymorphisms in or near CYP2C9, CYP3A4 and/or CYP2C19, optionally that are associated with cannabinoid metabolism. The recommended dosage may be for a specific variety of cannabis for treating a medical condition.

The invention discloses a kit for detecting the curative effect of an individual anti-angina pectoris drug. The kit comprises a specific primer pair and a specific fluorescent probe pair for detecting the polymorphic sites of an ALDH2 gene, a CYP3A4 gene, a CYP3A5 gene, a CYP2D6 gene and a CYP2C9 gene at the targeted use sites of the anti-angina pectoris drug, fluorescent quantitative PCR conventional components, etc. The kit estimates the curative effect of the individual anti-angina pectoris drug by detecting the polymorphic sites of the ALDH2 gene, the CYP3A4 gene, the CYP3A5 gene, the CYP2D6 gene and the CYP2C9 gene at the targeted use sites of the anti-angina pectoris drug.

The present invention discloses a kit for detecting human diabetes sensitive genes. The kit comprises a C11orf 65 primer group, a CYP2C9 primer group, a TCF7L2 primer group, an ABCC8 primer group anda KCNJ11 primer group. The human diabetes drug sensitive genes C11orf 65, CYP2C9, TCF7L2, ABCC8 and KCNJ11 are used as detection objects, and variations of the related genes can be rapidly, simply andaccurately detected by combining the specific primers and combining a nucleic acid mass spectrum detection technology.